Le Lézard
Classified in: Science and technology
Subject: PER

Systech International announces record third quarter performance


PRINCETON, N.J., Dec. 7, 2017 /PRNewswire/ -- Systech International, a global technology leader in serialization, track and trace and brand protection, today announced the company recorded its highest revenue in any third quarter and is positioned to close out its most profitable year in its 32-year history. This has been driven by the continued adoption of its comprehensive suite of software solutions. Its UniTracetm traceability software continues to expand in market share, its serialization solution is the de-facto standard for the pharma industry, and its UniSecuretm solution is gaining traction as the next evolution of true brand authentication.

Given this positive trajectory, founder Robert DeJean has announced he will retire from the day-to-day responsibilities of Chief Executive Officer to fully focus on his more strategic role as advisor and member of the board of directors. The company has enlisted an executive search firm to recruit a new CEO to continue working toward the vision to radically change the way companies build, protect, and grow their brands.

Michael Dubilier, Chairman of Systech's Board of Directors stated, "We are grateful for all Bob has done in the last 32 years to bring Systech to this critical juncture."

"With the strong leadership team in place, now is the perfect time to transition to a new CEO. I'm looking forward to working strategically with the executive team as we enter into this next exciting phase of the company," stated Mr. DeJean. "Our software platform, Uniquity, has successfully supported the serialization needs of the pharmaceutical industry for decades and we are deploying this platform to reach beyond just serialization into true brand protection and brand activation."

During our CEO search process, Kevin McKay, a longtime supporter, advisor, and consultant of Systech will be providing support to the board on certain aspects of the transition. Kevin's extensive executive experience with software solutions and services in the healthcare industry will be invaluable.

About Systech International: Systech pioneered serialization and is defining the future of authentication. For more than 30 years, Systech has led best practices for global brands across pharmaceutical, life sciences, and consumer packaged goods industries. Systech's presence includes offices in North America, Europe, India, and a partner network in South America, the Middle East, China, and Japan.

Contact:

Systech International
Sarah Paris-Mascicki
+1 7327639460
[email protected]

SOURCE Systech International


These press releases may also interest you

at 00:45
Claudio Bono, Managing Director for two independent Hotels in Silicon Valley, is thrilled to unveil a groundbreaking platform and an idea that will transform the landscape of the urgent unhoused crisis and social issues. Leveraging his extensive...

26 avr 2024
OKX, a leading Web3 technology company, today announced the integration of Side Protocol with the OKX Wallet. Side Protocol is a cross-chain middleware protocol designed to enable seamless communication and asset transfer between heterogeneous...

26 avr 2024
OKX, a leading Web3 technology company, today announced the integration of Biturbo with the OKX Wallet. Bitrubo is an innovative layer 2 solution that brings the power of Ethereum's smart contracts to the Bitcoin network. Biturbo is designed as an...

26 avr 2024
The report titled "Cognitive Security Market by Component (Services, Solutions), Security Type (Application, Cloud, Cybersecurity), Application, Deployment Mode, Enterprise Type, Vertical - Global Forecast 2024-2030" is now available on...

26 avr 2024
The report titled "Anti-Mullerian Hormone Test Market by Product (POC Testing, Self-check Kits), End-User (Commercial Labs, Research & development), Distribution, Use - Global Forecast 2024-2030" is now available on 360iResearch.com's offering,...

26 avr 2024
Rakovina Therapeutics Inc. a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies announced the financial results for its fourth quarter and fiscal year ending December 31, 2023 and...



News published on and distributed by: